Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

M. A. Socinski, C. J. Langer, I. Okamoto, J. K. Hon, V. Hirsh, S. R. Dakhil, R. D. Page, J. Orsini, H. Zhang, M. F. Renschler

Research output: Contribution to journalArticlepeer-review

88 Citations (Scopus)


Background: This analysis evaluates safety and efficacy in elderly (≥70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial. Patients and Methods: Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m2 weekly (nab-P/C) or solvent-based paclitaxel (Taxol) 200 mg/m2 day 1 every 3 weeks (sb-P/C). The primary end-point was overall response rate (ORR). Results: Fifteen percent of 1052 enrolled patients were elderly: nab-P/C, n = 74; sb-P/C, n = 82. In both age cohorts, the ORR was higher with nab-P/C versus sb-P/C (age ≥70: 34% versus 24%, P = 0.196; age <70: 32% versus 25%, P = 0.013). In elderly patients, progression-free survival (PFS) trended in favor of nab-P/C (median 8.0 versus 6.8 months, hazard ratio (HR) 0.687, P = 0.134), and overall survival (OS) was significantly improved (median 19.9 versus 10.4 months, HR 0.583, P = 0.009). In younger patients, PFS (median 6.0 versus 5.8 months, HR 0.903, P = 0.256) and OS (median 11.4 versus 11.3 months, HR 0.999, P = 0.988) were similar in both arms. Adverse events were similar in both age groups, with less neutropenia (P = 0.015), neuropathy (P = 0.001), and arthralgia (P = 0.029), and increased anemia (P = 0.007) with nab-P/C versus sb-P/C. Conclusions: In elderly NSCLC patients, nab-P/C as first-line therapy was well tolerated and improved the ORR and PFS, with substantially longer OS versus sb-PC.

Original languageEnglish
Pages (from-to)314-321
Number of pages8
JournalAnnals of Oncology
Issue number2
Publication statusPublished - Feb 2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Safety and efficacy of weekly nab<sup>®</sup>-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this